ABSTRACT: Myasthenia gravis (MG) is an archetypal autoimmune disease. The pathology is characterized by autoantibodies to the acetylcholine receptor (AChR) in most patients or to muscle-specific tyrosine kinase (MuSK) in others and to a growing number of other postsynaptic proteins in smaller subsets. A decrease in the number of functional AChRs or functional interruption of the AChR within the muscle end plate of the neuromuscular junction is caused by pathogenic autoantibodies. Although the molecular immunology underpinning the pathology is well understood, much remains to be learned about the cellular immunology contributing to the production of autoantibodies. This Review documents research concerning the immunopathology of MG, bringing together evidence principally from human studies with an emphasis on the role of adaptive immunity and B cells in particular. Proposed mechanisms for autoimmunity, which take into account that different types of MG may incorporate divergent immunopathology, are offered.
Patients with myasthenia gravis (MG) experience skeletal muscle weakness, which is worsened by activity. 1, 2 MG is a multifactorial disease that includes immune dysregulation, predisposing genetics, and environmental factors. The disease is rare; the estimated annual incidence is 1-2 per 100,000, and the prevalence ranges from approximately 7-20 per 100,000, according to regional studies performed since 1990. [3] [4] [5] Recent epidemiological investigations have indicated that, similarly to other autoimmune diseases, the incidence of MG is rising considerably. 6 Such increases can be partially attributed to improved diagnostic precision and rising longevity of the populace, but a genuine rise in incidence may indicate the important role of environmental contributions.
MG is an archetype for B-cell-mediated autoimmune disorders. The molecular immunopathology ( Fig. 1 ) is attributed to the presence of autoantibodies specifically targeting components of the acetylcholine receptor (AChR). The specific disease mechanism is defined by these autoantibodies and their recognition of a number of molecular elements of the AChR, which impairs neuromuscular transmission in the postsynaptic membrane. The specific end plate abnormalities mediated by the autoantibodies include disruption of receptor signaling and complement-directed tissue damage. Unlike many autoimmune diseases, MG autoantibodies are demonstrably pathogenic. [7] [8] [9] [10] [11] [12] This has been substantiated through numerous in vitro approaches and has perhaps been demonstrated most convincingly through passive transfer of patient-derived serum or immunoglobulin, which reproduces features of the disease in experimental animals. 13 Additional evidence is provided by documented examples of maternal-fetal autoantibody transmission 14, 15 and neonatal transfer, 16, 17 both of which can generate disease symptoms.
Genetic factors partially contribute to MG susceptibility. 18 Although families in whom more than 1 member has MG are rare, limited MG twin-pair studies have suggested rough approximations on MG concordance to be near 35% in monozygotic twins and near 5% in dizygotic twins. 19 These values, which are similar to a number of other autoimmune diseases, re-emphasize that varying degrees of both genetic and environmental factors contribute to the development of the disease. 20 Nearly all of the MG-associated genes currently identified are involved in the immune response, a pattern common to nearly all autoimmune diseases. 21 The human leukocyte antigen (HLA) locus remains the most strongly associated risk factor for the disease, especially HLA-DQA1. 22 Examples of other genes encoding molecules that are involved in immune modulation include CTLA4, PTPN22, TNFRSF11A 22 and TNFAIP3 interacting protein 1, 23 all of which participate in cell-signaling pathways.
The incidence of MG with AChR autoantibodies has been observed to distribute in a bimodal pattern. Cases of early-onset MG, defined as patients in whom symptoms occur before approximately 40 years of age, are predominantly in women. Conversely, the incidence of late-onset disease is higher in men than in women. MG with muscle-specific tyrosine kinase (MuSK) autoantibodies is found predominantly in women and has a peak incidence of less than 40 years of age. 24 Clinical classifications of MG include a number of subgroups. 25, 26 Ocular MG, which is restricted to isolated ptosis, diplopia, or both, with no signs or symptoms of weakness elsewhere, is often the first manifestation of the disease. In 40%-50% of ocular MG cases, autoantibodies are not detected. 27 This, however, does not exclude the possibility that they are present and causal. During this early stage of the disease, they may be below the level of detection of commonly used assays and/or may be enriched at the neuromuscular junction (NMJ), the site of disease pathology and, thus, not measurable in the serum.
Generalized MG usually includes symptoms associated with ocular disease as well as weakness in extremity, bulbar, and/or respiratory muscles. Autoantibody status is used to classify the disease and has treatment implications in some cases. AChR, MuSK, and low-density lipoprotein (LDL) receptor-related protein 4 (LRP4) autoantibody positive and autoantibody seronegative represent additional major subsets. Within the AChR-positive population, further subdivision categorizes earlyonset MG (EOMG) and late-onset MG (LOMG). EOMG is often characterized by thymic hyperplasia, whereas cases of LOMG have thymic abnormalities less frequently. Concomitant autoimmune diseases in patients with AChR MG are not uncommon, being reported in 13%-22% of patients.
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The most frequently associated autoimmune disease is thyroid disease, followed by systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
The production of autoantibodies clearly implicates a principal role for B cells in the disease FIGURE 1. Schematic diagram outlining the mechanistic hypothesis for the production of AChR or MuSK MG autoantibodies. The proposed mechanistic path to autoantibody production in MG begins with na€ ıve B cells (1, 2) , which likely encounter antigens and receive T-cell help in the lymph node (3). They then differentiate into memory B cells (4), antibody-secreting plasmablasts (5), and antibodysecreting long-lived plasma cells, which reside in the bone marrow (6A) and may also be present in the thymus (6B) of some patients with AChR MG. Plasmablasts and plasma cells may contribute to MG autoantibody production. B-cell-depletion therapy eliminates CD20 1 memory and na€ ıve B cells but does not directly eliminate plasmablasts or plasma cells, which are CD20
2
. After CD20-targeted depletion, MG serum autoantibody titers markedly diminish (especially in MuSK MG), suggesting that plasma cells are unlikely candidates for autoantibody production. Rather, short-lived plasmablasts are more viable candidates. Because only a small fraction of these cells express CD20, the effectiveness of B-cell-depletion therapy may depend on depletion of a pool of plasmablast-progenitor CD20 1 memory B cells. Conversely, autoantibody titers that remain elevated following CD20-targeted depletion may be the product of longlived plasma cells.
pathogenesis. Dysregulation in immune cell types extending beyond B cell lineages have been documented, indicating that a combination of factors contributes to disease manifestation; this theme is largely consistent throughout human autoimmunity. The contributions of B cells to the production of MG autoantibodies have been the focus of investigative interests, especially with the successful introduction of biological therapeutics that target these cells. This Review focuses on the contributions that B cells make to the immunopathology of AChR, MuSK, and other subtypes of MG, although studies outside of AChR MG remain limited in number. We highlight T-cell subsets that affect Bcell responses, tissue compartments harboring B cells, B-cell and antibody-secreting subsets, and therapeutic intervention. Thymoma-associated MG and animal models are not included.
B-CELL-MEDIATED MG IMMUNOPATHOLOGY INFLUENCED BY T CELLS
The autoantibodies in AChR MG are class switched, somatically mutated, and primarily of the immunoglobulin G (IgG) 1 subclass. The initiation of the process that produces this affinity-driven maturation is dependent on T-cell help. Accordingly, CD4 T cells are the main drivers in the immunopathogenesis of MG disease.
29-33 They play a multifaceted role in immunity, from promoting inflammation to inducing immune tolerance and supporting B-cell function. In MG, each of these roles has been demonstrated to be dysregulated, resulting in the production of autoantibodies and secretion of proinflammatory cytokines. Specifically, AChR-specific CD4 T cells produce interferon (IFN 42 Quantitatively, reports on the frequency of Tregs in patients with MG have been mixed, with some groups showing a decrease in the frequency of Tregs in MG, [43] [44] [45] [46] whereas others show no such alteration. 40, 41, 47, 48 The differences could be attributed to the markers that were used to identify Tregs. Before FOXP3 was identified as the transcription factor for Tregs, Tregs were identified only by the expression of CD25. Collectively, the functional assays for Tregs provide the best support for their role in the disease because they show that Tregs in patients with MG are defective in regulating immune responses compared with those in healthy subjects.
T-Follicular Helper and T-Follicular Regulatory Cells.
AChR MG is a CD4-dependent B-cell-mediated disease; therefore, the interaction of T-follicular helper (Tfh), T-follicular regulatory (Tfr), and B cells are critical in dictating the development of MG disease. In 1988, before Tfh cells were recognized as a distinct CD4 T cell subset, it was demonstrated that CD4 T cells were critical in the production of anti-AChR autoantibodies by B cells. [30] [31] [32] [33] 49 Now it is well understood that CD4 T cells differentiate into Tfh cells upon expression of the master transcription factor B-cell lymphoma 6 (Bcl6) and surface marker CXCR5, allowing migration into the germinal center where they support differentiation of B cells into memory B cells and antibody-secreting subsets (plasmablasts and plasma cells). 50, 51 In the thymus of patients with MG, the frequency of Tfh cells and B cells increased along with the expression of the Tfhassociated markers, IL-21, PD-1, and ICOS on thymocytes. 52 ,53 CXCR5 1 CD4 T cells are also found in the periphery, and it is suspected that they are memory Tfh cells that have migrated out of the germinal center. 54 Circulating Tfh cells, IL-21, and CXCL13 were found at a higher frequency in patients with MG and correlated with disease severity. 55, 56 To demonstrate the pathogenic role of Tfh cells in EAMG, knockdown of the Tfh transcription factor Bcl6 decreased the frequency of Tfh cells and IL-21 production and, importantly, diminished disease severity. 57 Tfr cells are counterparts to Tfh cells that suppress Tfh and B-cell interactions in the germinal center. [58] [59] [60] Similarly to Tfh cells, Tfr cells express CXCR5, PD-1, ICOS, and Bcl6. However, unlike Tfh cells, Tfr cells are derived from natural Treg precursors and express FOXP3 and B lymphocyteinduced maturation protein-1 (BLIMP-1). 61 Tfr can suppress the production of IL-21 and IL-4 by Tfh cells and inhibit class switching and antibody production by B cells. In MG, the increase in Tfh cells is likely due to a dysregulation in Tfr cells because patients with MG exhibit lower ratios of Tfr/Tfh cells and frequency of Tfr cells. 62, 63 Going forward, a better understanding of the dynamics among Tfh, Tfr, and B cells in immune tolerance and disease pathogenesis is essential.
B-CELL PRODUCTS: IMMUNOGLOBULINS THAT DRIVE MG PATHOLOGY
Studies conducted many decades ago sought to identify the circulating agent(s) that caused blocking of neuromuscular transmission in MG. 64, 65 Through continued efforts that built upon these and many other early investigations, it is now well understood that the molecular immunopathology of MG is due to the presence of circulating autoantibodies specifically targeting the AChR, MuSK, or LRP4. Patient-derived AChR, MuSK, and LRP4 autoantibodies in MG are demonstrably pathogenic. [7] [8] [9] [10] [11] [12] 66 Patients most often harbor only 1 of these autoantibody specificities. In approximately 75%-80% of patients with MG, AChR autoantibodies are detectable; MuSK autoantibodies are found in another 5%-10%, and LRP4 autoantibodies account for up to 20%-30% of those without AChR or MuSK autoantibodies. 67, 68 This leaves about 5%-10% of patients with MG without detectable serum autoantibodies to either AChR, MuSK, or LRP4, which is termed seronegative. 67, 68 However, the presumption that autoantibodies are absent in such cases is likely incorrect and requires alternative (autoantibody-independent) models to describe the pathology. The introduction of cellbased assays that express MuSK or clustered AChR was instrumental in demonstrating that a considerable portion of patients with MG who had been previously characterized as seronegative did indeed have autoantibodies present in their serum. 69, 70 Their autoantibodies were simply not detectable by the commercially available and commonly used radioimmunoassay. 71 Accordingly, it is anticipated that seronegative MG will continue to yield to the influence of higher sensitivity assays and to the discovery of new autoantigen targets. [72] [73] [74] AChR Autoantibodies. In the most common form of MG, autoantibodies directed against AChR are predominantly IgG1 and IgG3. These 2 subclasses effectively activate complement, leading to the formation of the membrane attack complex. [75] [76] [77] Autoantibody and complement-mediated damage to the NMJ impairs neuromuscular transmission through damage to the postsynaptic NMJ in the form of simplification of postsynaptic junctional folds, removal of AChR from the membrane, and widening of the synapse. 78 Thus, AChR function is impaired by a number of autoantibody-mediated functions: complement-mediated tissue injury and removal of AChR from the muscle membrane (probably a major factor), cross-linkage of divalent AChR autoantibodies that results in internalization of AChR (by modulating autoantibodies), and, rarely, a direct blockade of AChR by the autoantibodies. [79] [80] [81] [82] [83] [84] MuSK Autoantibodies. MuSK is thought to play an important role in clustering AChR at the NMJ to promote efficient neuromuscular transmission. Passive transfer and active immunization studies in animals have shown that MuSK autoantibodies are pathogenic. 85, 86 In contrast to AChR MG, MuSK autoantibodies are predominantly IgG4 and do not effectively activate complement. 87 Thus, the pathogenesis of MuSK MG is likely not complement mediated, and disruption of the interaction between MuSK and the postsynaptic protein LRP4 and collagen Q may be the predominant pathologic mechanism of MuSK autoantibodies. [88] [89] [90] An interesting feature of secreted IgG4 antibodies is their ability to engage in "Fab-arm exchange," whereby a monospecific IgG4 protein may swap a heavy and light chain pair with another IgG4 to become bispecific. 91 It has recently been shown that Fab-arm-exchanged antibodies are present in MuSK MG patients. 92 Other Autoantibodies in MG. Recent studies of patients with AChR or MuSK autoantibodies undetectable by standard assays have revealed additional autoantibodies specific to other NMJ proteins, including LRP4, agrin, collagen Q, cortactin, and the voltage-gated potassium channel Kv1.4. [93] [94] [95] [96] [97] [98] [99] [100] LRP4 autoantibodies are predominantly IgG1, and studies suggest that they are pathogenic. 66 Pathogenicity of the other autoantibodies remains unclear at the moment. Titin autoantibodies, which are known to be present in AChR autoantibody-positive patients with thymoma and in LOMG, have recently been observed in patients without identifiable autoantibodies to AChR, MuSK, or LRP4 by using a high-sensitivity radioimmunoprecipitation assay. 101 These findings suggest that titin autoantibodies may play a role as a diagnostic marker, but independent replication with a large collection of patients with MG including those with and without thymoma is required.
THE CONTRIBUTIONS OF B-CELL SUBSETS TO MG IMMUNOPATHOLOGY B-cell Tissue Compartments in MG.
The compartmentalized enrichment of disease-associated B cells can occur in tissue-specific autoimmunity. 102 For example, at the synovium, the site of tissue injury in patients with rheumatoid arthritis, B cells producing autoantibodies that are directed toward citrullinated protein/peptide antigens can be observed. 103 Although the site of tissue injury in AChR MG is the muscle end plate, the residence of B cells that express AChR autoantibodies is widely diverse (Fig. 1) . Over 4 decades ago, AChRspecific IgG was found in the MG thymus. 104 Shortly afterward, the first identification of AChR autoantibody-producing B cells that occupied the thymus was reported. 105 Thymic abnormality, defined by an AChR-specific immune infiltrate, is now recognized as a fundamental characteristic of many (but not all) patients with AChR MG.
The thymus in a subset of patients with MG includes 106 AChR expression by thymic epithelial cells and myoid cells, the presence of proinflammatory cytokines, and defective regulatory T cells. 42 B-cell-supporting CD4 1 helper T cells are also present. 107 B cells populating the hyperplastic thymus express markers of activation and display functional signs of activation. 108 B cells often organize in the hyperplastic thymus within tertiary lymphoid organs, frequently exemplifying many characteristics of germinal centers. The presence and frequency of these structures positively associate with circulating AChR autoantibodies, reflecting a contributory role in their production. Although these characteristics of AChR MG thymus tissue are seminal, they are not applicable to the entire MG population, given that the thymus of approximately 30% of patients with AChR MG is not hyperplastic and, therefore, may contain only few, if any, disease-associated B cells. 109 The B cell subset in the thymus tissue that is responsible for the detectable AChR autoantibody has not been precisely defined, but spontaneous production of AChR autoantibodies was demonstrated as most likely due to resident plasma cells, 110, 111 with possible contributions from plasmablasts. Additional studies demonstrated that AChR autoantibody production by thymic lymphocytes can occur spontaneously or with mitogen stimulation, suggesting that heterogeneous B cell populations make such contributions. 112, 113 AChRspecific CD27
1 memory B cells are also likely to be present in the hyperplastic MG thymus, although specific identification of such has not been formally demonstrated. B-cell repertoire sequencing and B-cell immortalization studies have shown that the B cells resident in the MG thymus are broadly, clonally heterogeneous because they lack a dominant clone among the infiltrate. 114, 115 They harbor the characteristics of antigen experience, including somatic hypermutation 114, [116] [117] [118] [119] and biased usage of variable region gene segments, which include overrepresentation of the heavy-chain variable 3 (VH3) family at the expense of VH4 genes. 114 Of course, among these sequenced B cells are those producing autoantibodies directed toward AChR. However, they represent a minor fraction of the total B-cell infiltrate because they are not highly enriched. 111, 120 Given the major role of the thymus in MG AChR autoantibody production, thymectomy has been a long-standing treatment strategy. Although thymus resection does not extinguish the disease in most cases, a recent, large, placebo-controlled clinical trial has confirmed the long-held belief that the procedure is beneficial. 121 The AChR antibody titer in the majority of patients with MG who have had a thymectomy does fall but, invariably, does not reach undetectable levels. 122, 123 Provided that all of the thymus tissue harboring immune infiltrate is surgically removed, the persistence of both disease and autoantibody is a strong indication that additional locations host autoantibodyproducing B cells.
AChR autoantibody-producing B cells can also be found in the circulation 30,124 and lymph nodes. 125 . Measurement of AChR-specific B cells present in the circulation is often positively associated with thymic hyperplasia and high serum autoantibody titers. 124 AChR autoantibody-producing B cells have also been identified in the bone marrow. 126 The bone marrow is a well-recognized niche for long-lived plasma cells that directly contribute to the majority of serum immunoglobulin and are accordingly responsible for serological memory. Plasma cells in the bone marrow that produce AChR autoantibodies may contribute to persistently elevated titers after thymectomy 127 and other treatments 128 (discussed below). Do lymphocytes, including autoantibodyproducing B cells, gather at the site of tissue injury, the NMJ? Lymphocytes that localize to the end plate region have been observed in the muscle tissue of patients with AChR MG. [129] [130] [131] Localization in regions that include evidence of tissue damage has also been reported, 132 although the specific lineage of such cells was not always elucidated. A subsequent investigation reported macrophages and T cells in MG muscle tissue, but, overall, these infiltrates include few cells, are infrequently found at end plates, and are present in only a subset of patients. 76 Overall, the presence of lymphocytic infiltrates does not appear to associate with the loss of AChR from the end plates. 76 Although clonal B-cell enrichment in the hyperplastic thymus tissue is conspicuous, perturbations in periphery are more difficult to observe. The circulating B-cell repertoire was recently characterized through analysis of over 500,000 unique sequences; however, only minor, albeit important, deviations from normal controls were evident. 133 This indicates that pathogenic B cells make small changes to the global repertoire that are not readily perceived without very large data sets. Finally, the thymus of patients with MuSK MG presents a picture that is quite different from that of patients with AChR MG. Immune-cell infiltrates and ectopic germinal centers that are frequently found in the AChR MG thymus tissue are rarely present in MuSK MG. 134 This infers that MuSK autoantibodies may develop and reside in a compartment other than the thymus. 
IgD
2 ) B cells, the frequency of which is elevated in some autoimmune diseases 135 and associated with disease-specific autoantibody titer, 136 do not appear to be altered in AChR MG. 137 A subpopulation of B cells expresses CD5
1 . These cells may be associated with autoantibody production and regulation, although their role in immunobiology is not unambiguously defined. Several autoimmune diseases, such as SLE and Sjogren syndrome, are associated with enhanced frequencies of CD5 1 B cells. Similarly, there appears to be an increase in CD5
1 B cells in a subset of patients with AChR MG. 138 Plasmablast frequency, including recently activated subsets (HLA-DR hi ) in ocular MG, is elevated in a some patients with AChR MG. 137 Although such phenotyping studies can identify subset abnormalities that are likely related to autoimmunity, their limitation lies in that identification of autoantibody producers is not possible.
Regulatory B Cells. Regulatory B cells (Bregs) are a rare B-cell subset with a profound effect in promoting immune tolerance. They inhibit T-cell expansion through IL-10, transforming growth factor (TGF)-b, and IL-35 and support the differentiation of T cells into Tregs. 139 hi145 B cells have been described to contain an enriched population of Bregs. Recent studies suggest that Bregs are antigen-specific and expand in the presence of an inflammatory event. 140, 146 However, the mechanisms driving their generation and maintenance remain undefined.
B10 cells, which are B cells identified by the production of IL-10, an immunosuppressive cytokine, constitute one of the better described subsets of Bregs. In humans, B10 cells represent 0.3%-0.8% of total B cells and decrease in number with age. 142 Because of their low frequency in circulation, and in an attempt to profile B10 cells better, B10 cells are expanded into B10 progenitor cells by a multiday toll-like receptor stimulation with recombinant CD40L, followed up by a restimulation with phorbol 12-myristate 13-acetate and ionomycin to detect IL-10 by flow cytometry. 142 In 2014, the first MG study examining B10 cells revealed a decrease in the frequency of B10 cells and a subset of CD24 1 CD38 1 B cells in AChR and MuSK MG compared with healthy controls. 147 This decrease in the frequency of B10 cells correlated with disease severity based on MG Foundation of America clinical classification assignments. Disease severity also correlated with the functional ability of B10 cells to suppress CD4 T-cell proliferation. 148 Additionally, examination of patients undergoing rituximab treatment revealed that the repopulation of B10 cells was associated with the responsiveness to rituximab treatment. Although several EAMG and patient studies have supported the decrease in the frequency of B10 cells in MG, the mechanisms that limit B10 differentiation and their function have not yet been elucidated. [149] [150] [151] Going forward, additional research is required to validate B10 cell frequencies as a biomarker of MG disease severity, and methods to increase B10 cell frequencies may hold promise as a treatment for MG. B-cell tolerance also functions improperly in both AChR and MuSK MG patients. 156 Accordingly, the na€ ıve B-cell repertoire in MG is shaped in the context of abnormal counter selection during B-cell development (that is, self-reactive cells are not eliminated). It follows that the manifestation of this abnormality is a na€ ıve repertoire that is shaped differently from those in which B-cell tolerance functions normally (Fig. 1) . Next-generation deep sequencing allows for the comprehensive evaluation of the B-cell receptor (BCR) repertoire properties in health and disease and provides the depth necessary to depict adequately the circulating peripheral repertoire, which includes up to 10 11 B cells in humans. 157 Application of this approach to the na€ ıve B-cell compartments in patients with AChR and MuSK MG revealed repertoire features that were not observed when B-cell tolerance functioned properly. 133 This emphasizes the impact of tolerance defects on peripheral autoimmune repertoires. It remains to be determined whether the autoreactive na€ ıve B-cell pool is the reservoir from which disease-associated autoantibodies are derived.
THERAPEUTICS Rituximab and New Biologicals That Target B
Cells. Rituximab is a clinically approved B-celldirected biologic. It is a chimeric monoclonal antibody that targets the CD20 antigen found on subsets of the B-cell lineage. CD20 is a 33-kDa protein expressed by all mature B cells but not on pre-B or differentiated plasmablasts and plasma cells. Rituximab has been used as part of the standard therapy for non-Hodgkin lymphoma and has emerged as a highly effective tool in the management of certain autoimmune diseases. 158, 159 Interest in its use for MG began after a patient with both lymphoma and MG responded favorably to rituximab. 160 Several recent studies 128, [161] [162] [163] [164] have demonstrated the benefits of rituximab treatment in MG. In addition to significant clinical improvement, rituximab also allowed for tapering and subsequent discontinuation of other immunotherapies in both AChR and MuSK MG patients. 163 The beneficial effect, although durable, is not permanent, given that postrituximab relapses have been observed. 165 The B-cell repertoire that re-emerges following CD20-mediated B-cell depletion therapy includes evidence of tolerance dysfunction in autoimmune conditions shown to have the checkpoint abnormalities prior to treatment. 166 This indicates that CD20-mediated depletion does not restore checkpoint function and suggests that disease manifestation may re-emerge if the abnormal repertoire contributes to pathology.
Given that MG is a B-cell-mediated disease, the mechanism by which rituximab takes action may seem apparent. That is, B cells are depleted, which results in diminished pathogenic autoantibody production. However, a careful look uncovers that it may be more complicated (Fig. 1) . Long-lived plasma cells secrete the majority of circulating immunoglobulin. Given the absence of CD20 on their surface, they are not directly affected by rituximab. This is supported by unchanged immunization-generated and plasma celldependent antibody titers, such as those for tetanus, following anti-CD20 B-cell depletion. 128 As described above, it is apparent that plasma cells and/or plasmablasts produce AChR autoantibodies. In AChR MG, the autoantibody titer can remain positive after treatment with rituximab, even during clinical improvement. 128 Therefore, it is not exactly clear how the treatment affects improvement. Similarly, neuromyelitis optica (NMO) autoantibodies directed toward the aquaporin 4 (AQP4) water channel do not fall correspondingly even though remarkable clinical improvement follows rituximab treatment. 167 Although these collective data may reflect compartmentalization (in the muscle or central nervous system [CNS]) of the respective autoantibodies and/or discordance of serum titer with disease activity, they may also suggest that additional mechanisms, in addition to those associated with autoantibody, may promote disease activity, at least in the case of NMO. In AChR MG, given the clear dependence of immunopathology on autoantibodies, it is likely that rituximab eliminates autoantibody-producing cells, but the compartment and specific cells remain to be identified. The persistence of a positive autoantibody titer in responding patients may reflect the inability of the assays to discriminate between detection of these autoantibodies and their pathogenic properties and/or that the serum does not reflect autoantibody status in the CNS tissue (in NMO) or neuromuscular junction (in MG).
The situation in MuSK MG may be quite different from that in AChR MG (Fig. 1) . The markedly diminished MuSK autoantibody titer, as early as 3 months after rituximab-mediated CD20
1 B-cell depletion, 128 suggests that long-lived plasma cells are not likely to be major contributors to MuSK autoantibody production. Rather, short-lived antibody-secreting cells such as plasmablasts are viable candidates as the primary driver of MuSK autoantibody production. Because only a small fraction of these cells express CD20, 168 the effectiveness of rituximab in MuSK MG may depend upon depletion of a pool of plasmablast-progenitor CD20
1 memory B cells. 168, 169 Our group has experimentally tested this model, and the results suggest that plasmablasts do indeed contribute to the production of MuSK-specific autoantibodies. 170 Provided that plasmablasts or plasma cells, the majority of which lack CD20, 168 are a major source of pathogenic AChR autoantibodies, there are existing biologics that can effectively target these cells through their expression of CD19. Inebilizumab (formerly MEDI-551) is an anti-CD19 antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B-cell lineages. The drug is currently being evaluated in NMO given the known role of plasmablasts in AQP4 autoantibody production. 171, 172 A similar evaluation in AChR MG has not been initiated, but, given the similarities in these diseases, testing in rituximab-resistant patients could be considered.
MG INDUCTION; A SIDE EFFECT OF CANCER IMMUNOTHERAPY
The immune system is equipped with checkpoints that enforce immune homeostasis. Our immune system uses these checkpoints as a balance to prevent an immune response against selfantigens and, thus, the onset of autoimmune diseases such as MG. Moreover, these checkpoints fine tune the immune response against pathogens to activate immune cells efficiently and subsequently shut down their effector functions after the pathogen is removed to prevent immunopathogenesis. With an improved understanding of the mechanisms and the key proteins surrounding immune checkpoints, recent developments in cancer immunotherapy have focused on therapies that intervene in the biology of immune checkpoints to promote T-cell activation. 173 In the tumor microenvironment, one mechanism of immune evasion by tumor cells is the binding of inhibitory ligands with their corresponding receptors. It is significant that T cells in the tumor microenvironment highly express inhibitory receptors, and this interaction shuts down the effector function of T cells. Thus, the goal of checkpoint blockade therapy is to tilt this balance toward immune activation by blocking the interaction of inhibitory receptors with their ligands, promoting the generation of efficient tumor-eliminating T cells. Two of the well-studied immune checkpoint targets that have changed the landscape of cancer therapy are CTLA-4 and PD-1.
174,175 CTLA-4 is upregulated after T-cell activation and competes with CD28 for binding to B7-1 and B7-2. This competition favors CTLA-4 because CTLA-4 has a higher affinity than CD28 to B7-1 and B7-2 and subsequently results in immune suppression. PD-1 is an inhibitory receptor that is upregulated following T-cell activation and inhibits T cell function.
Given the the mechanisms behind immunotherapy, it is no surprise that the main side effect of unleashing the control of the immune response has been immune-related disease manifesting as dermatologic, endocrine, gastrointestinal, and hepatic events. Although cases of MG after such immunotherapy are rare, the exacerbation of MG is a vital health concern that must be carefully monitored. 176 The first record of ipilimumabinduced (anti-CTLA4) MG was described in 2 patients with melanoma. 177 The functional burden caused by the development of MG contributed to the death of 1 patient, whereas the other patient improved after plasmapheresis. In lung cancer, MG symptoms were reported after combination therapy with either PD-1 or PD-L1 and CTLA-4 inhibitors. 178, 179 In these particular cases, the patients developed complications associated with MG exacerbation and did not survive. There are also cases of checkpoint blockade therapy in patients with known history of MG. 180, 181 In each of these cases, the patients were given anti-PD-1 therapy to treat melanoma but developed an exacerbation of their MG. Fortunately, their MG symptoms resolved, and, although anti-PD-1 therapy was discontinued, the patients had stable disease or saw a shrinkage of their tumors.
The mechanism by which anti-CTLA-4, anti-PD-1, or anti-PD-L1 therapy induces MG disease is undefined. Available case reports describe a rapid progression to myasthenic crisis; therefore, any neurologic event must be recognized early, and immunotherapy must be discontinued immediately and then likely followed by initiation of high-dose steroids along with intravenous immunoglobulin or plasmapheresis. Immunologically, these studies suggest that the MG-specific B and T cells are present in people with no prior clinical evidence of MG pathology. Although these autoreactive cells are normally suppressed through immunetolerance mechanisms, the introduction of checkpoint blockade therapies decreases the ability of T cells to discriminate self and nonself. It is not clear whether the checkpoint-inhibitor-induced disease emulates the typical form in terms of immunobiology. Autoantibody specificity and participating cell types first must be identified so similarities can be defined.
Collectively, with immunotherapy becoming front-line treatment for many cancer types, the number of reports describing exacerbated or emerging MG following the use of checkpointinhibitor immunotherapy continues to grow rapidly. [182] [183] [184] Therefore, prior to treatment, patients must be carefully scrutinized for any autoimmune diseases, family history of such, and current physical condition. Knowing a patient's likelihood of an adverse event following immunotherapy assists clinicians in maximizing the power of immunotherapy while limiting side effects.
FUTURE DIRECTIONS AND CONCLUSIONS
Our understanding of MG immunopathology remains incomplete. It appears that the mechanism used by B cells for autoantibody production in AChR and MuSK MG differ, but details of both are essential to understand the immunopathology that will guide the development of more effective therapies. Clinicians require superior biomarkers that accurately associate with disease activity and severity to help guide management. Directly measuring autoantibody-producing B cells may fulfill this requirement. The B-cell response in MG most certainly requires T-cell help. Although it is understood that proinflammatory antigen-specific T cells are at work in AChR MG, very little is known about the role of T cells in MuSK or LRP4 MG.
Translational B-cell studies that will have the most impact on the care and treatment of patients are likely to include further investigation of B-cell depletion in MG disease subsets, including MuSK MG. Evaluation of second-generation B-cell-directed biologics such as ocrelizumab, which appear to have improved efficacy and may be better tolerated over the first generation, should be considered. 185 However, highly specific treatment is desired over broad approaches that target an entire immune-cell lineage. Autoantigen-based chimeric immunoreceptors that can direct T cells to kill autoreactive B cells through the specificity of the BCR have been developed for the B-cell-mediated autoimmune disease pemphigus. 186 Such an approach may provide an effective strategy for specific targeting of autoreactive B cells in MG, resulting not only in clinical improvement but also in an improved safety profile over other less specifically targeted agents.
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